The company said, “Incyte’s (INCY) guidance for the fiscal year 2025 is summarized below. Incyte is raising its full year 2025 net product revenue guidance to $4.23 – $4.32 billion to account for higher demand for Jakafi and other hematology and oncology marketed products. The update includes raised guidance for Jakafi to $3.050 – $3.075 billion, as well as other hematology and oncology marketed products to $550 – $575 million. Incyte is reaffirming its guidance across all other categories.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte reports Q3 EPS $2.26, consensus $1.64
- Incyte’s Ruxolitinib Cream Study: A Potential Game-Changer for Hidradenitis Suppurativa
- Incyte’s Ruxolitinib Cream Study: A Potential Breakthrough for Pediatric Vitiligo
- Incyte’s Latest Clinical Study: A Step Forward in Drug Development
- Incyte’s Phase 3 Study on Povorcitinib: A Potential Game-Changer for Prurigo Nodularis